進行非扁平上皮非小細胞肺がんの一次治療において、ペメトレキセド+白金製剤を含む化学療法への抗PD-L1抗体アテゾリズマブの併用効果を検証するIMpower132試験においてPFSを有意に延長、WCLC 2018で発表【スイス・Roche】

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced results from the Phase III IMpower132 study of Tecentriq® (atezolizumab) plus pemetrexed and platinum-based chemotherapy (cisplatin or carboplatin) for the initial (first-line) treatment of people with non-squamous, non-small cell lung cancer (NSCLC).

 

コメント

Leave a comment

Your email address will not be published.


*